Dose-finding Study Comparing Efficacy and Safety of a PARP Inhibitor Against Doxil in BRCA+ve Advanced Ovarian Cancer (ICEBERG 3)
A Phase II, Open-Label, Randomised, Comparative, International Multicentre Study to Assess the Safety and Efficacy of Different Doses of AZD2281 Given Orally Twice Daily Versus Intravenous Liposomal Doxorubicin Given Monthly in Patients With Advanced BRCA1- or BRCA2-Associated Ovarian Cancer Who Have Failed Previous Platinum-based Chemotherapy
Sponsor: AstraZeneca
This PHASE2 trial investigates Ovarian Neoplasms and is currently completed. AstraZeneca leads this study, which shows 13 recorded versions since 2008 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
13 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Dec 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE2
▶ Show 8 earlier versions
-
Jan 2020 — Jan 2021 [monthly]
Completed PHASE2
-
Nov 2018 — Jan 2020 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Jul 2018 — Nov 2018 [monthly]
Active Not Recruiting PHASE2
-
Jun 2018 — Jul 2018 [monthly]
Active Not Recruiting PHASE2
-
Sep 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
-
Jul 2017 — Sep 2017 [monthly]
Active Not Recruiting PHASE2
-
Feb 2017 — Jul 2017 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
Jul 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
For direct contact, visit the study record on ClinicalTrials.gov .